These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 364589)

  • 41. The success of precaution? Managing the risk of transfusion transmission of variant Creutzfeldt-Jakob disease.
    Wilson K; Ricketts MN
    Transfusion; 2004 Oct; 44(10):1475-8. PubMed ID: 15383021
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Inactivation and removal of prions in producing medical products. A contribution to evaluation and declaration of possible methods].
    Bertram J; Mielke M; Beekes M; Lemmer K; Baier M; Pauli G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2004 Jan; 47(1):36-40. PubMed ID: 15205822
    [No Abstract]   [Full Text] [Related]  

  • 43. Methods to minimize the risks of Creutzfeldt-Jakob disease transmission by surgical procedures: where to set the standard?
    Sutton JM; Dickinson J; Walker JT; Raven ND
    Clin Infect Dis; 2006 Sep; 43(6):757-64. PubMed ID: 16912952
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prion diseases and infection control precautions.
    Luny E
    Dent Today; 2005 Apr; 24(4):106-7. PubMed ID: 15884616
    [No Abstract]   [Full Text] [Related]  

  • 45. Inactivation of BSE agent.
    Taylor DM
    Dev Biol Stand; 1991; 75():97-102. PubMed ID: 1794635
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ophthalmological precautions in Creutzfeldt-Jakob disease.
    Fross RD
    Ann Neurol; 1986 Dec; 20(6):748. PubMed ID: 3545051
    [No Abstract]   [Full Text] [Related]  

  • 47. [Disinfection and sterilization of endoscopes in urology. The Committee on Infection of the French Association of Urology].
    Lobel B; Abbou C; Anidjar M; Blitz M; Leroux P; Mignard JP; Sachot JL
    Prog Urol; 1997 Jun; 7(3):505-7. PubMed ID: 9232637
    [No Abstract]   [Full Text] [Related]  

  • 48. Proposal for a procedure for complete inactivation of the Creutzfeldt-Jakob disease agent.
    Taguchi F; Tamai Y; Uchida K; Kitajima R; Kojima H; Kawaguchi T; Ohtani Y; Miura S
    Arch Virol; 1991; 119(3-4):297-301. PubMed ID: 1877889
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Practical methods for chemical inactivation of Creutzfeldt-Jakob disease pathogen.
    Tateishi J; Tashima T; Kitamoto T
    Microbiol Immunol; 1991; 35(2):163-6. PubMed ID: 1909414
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Jakob-Creutzfeldt disease: brief review and precautionary measures.
    Harati Y; Mitchell C
    Tex Med; 1978 Aug; 74(8):52-4. PubMed ID: 354072
    [No Abstract]   [Full Text] [Related]  

  • 51. Studies of a novel agent possessing resistance to moist heat and disinfectants: parallels with Creutzfeldt-Jakob agent.
    Dyas AC; Burdon DW
    J Hosp Infect; 1990 Apr; 15(3):265-72. PubMed ID: 1971633
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Classic Creutzfeldt-Jakob Disease in Canada. An infection control guideline. Health Canada.
    Health Canada
    Can Commun Dis Rep; 2002 Nov; 28 Suppl 5():1-84. PubMed ID: 12683358
    [No Abstract]   [Full Text] [Related]  

  • 53. A novel replicating agent isolated from the human intestinal tract having characteristics shared with Creutzfeldt-Jakob and related agents.
    Burdon DW
    J Med Microbiol; 1989 Jun; 29(2):145-57. PubMed ID: 2659797
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Creutzfeldt-Jakob under control.
    Br Med J; 1978 Feb; 1(6111):463-4. PubMed ID: 342063
    [No Abstract]   [Full Text] [Related]  

  • 55. Precautions in conducting biopsies and autopsies on patients with presenile dementia. Technical note.
    Traub RD; Gadjusek DC; Gibbs CJ
    J Neurosurg; 1974 Sep; 41(3):394-5. PubMed ID: 4606924
    [No Abstract]   [Full Text] [Related]  

  • 56. Newer data on the inactivation of scrapie virus or Creutzfeldt-Jakob disease virus in brain tissue.
    Brown P; Rohwer RG; Gajdusek DC
    J Infect Dis; 1986 Jun; 153(6):1145-8. PubMed ID: 3084671
    [No Abstract]   [Full Text] [Related]  

  • 57. Demonstration of the transmissible agent in tissue from a pregnant woman with Creutzfeldt-Jakob disease.
    Tamai Y; Kojima H; Kitajima R; Taguchi F; Ohtani Y; Kawaguchi T; Miura S; Sato M; Ishihara Y
    N Engl J Med; 1992 Aug; 327(9):649. PubMed ID: 1640969
    [No Abstract]   [Full Text] [Related]  

  • 58. Phenolized formalin may not inactivate Creutzfeldt-Jakob disease infectivity.
    Taylor DM
    Neuropathol Appl Neurobiol; 1989; 15(6):585-6. PubMed ID: 2693993
    [No Abstract]   [Full Text] [Related]  

  • 59. Creutzfeldt-Jakob disease with demonstration of virus-like particles.
    Shibayama Y; Sakaguchi Y; Nakata K; Goto T; Nakai M; Takai T; Shirakata S
    Acta Pathol Jpn; 1982 Jul; 32(4):695-702. PubMed ID: 7051752
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Transmissible virus dementia: slowly developing lethal encephalopathy caused by unconventional viruses. Findings in the various counties of the Slovak Socialist Republic (author's transl)].
    Mayer V; Orolin D; Mitrová E
    Bratisl Lek Listy; 1978 Oct; 70(4):507-19. PubMed ID: 363244
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.